A Phase III, International, RAndomized, Double-BLind, Parallel-Group, Multi-Center, Study to Assess the Efficacy of ZD6474 Versus Erlotinib (TARCEVA) in Patients with Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC)

Grants and Contracts Details

StatusFinished
Effective start/end date1/1/07 → 12/31/10

Funding

  • AstraZeneca Pharmaceuticals AB: $20,252.00